• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TScan Therapeutics, Inc. - Common Stock (NQ:TCRX)

0.2416 +0.0134 (+5.87%)
Delayed Quote Updated: 3:15 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 522,962
Open 0.2282
Bid (Size) 0.2400 (4,700)
Ask (Size) 0.2431 (100)
Prev. Close 0.2282
Today's Range 0.2279 - 0.2474
52wk Range 0.2243 - 2.570
Shares Outstanding 23,976,942
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Unusual volume stocks in Tuesday's session ↗
September 08, 2026
Via Chartmill
What's going on in today's session ↗
September 02, 2026
Via Chartmill

Performance

52-Week Range 90.6% below 52-week high
0.2416
0.2252W Low 2.5752W High
1 Week 26.8% below 1-week high
0.221W Low 0.331W High

TScan Therapeutics, Inc. - Common Stock (TCRX) traded between $0.22 and $2.57 over the past 52 weeks and last traded at $0.24, 90.6% below its 52-week high. Over the past week it ranged between $0.22 and $0.33.

Past 12 Months
-24.6%
-29.9%
-77.2%
-77.2%
-76.3%
-87.8%
1W -$0.08
1M -$0.10
3M -$0.82
6M -$0.82
YTD -$0.78
1Y -$1.74

TCRX was -87.8% over the past year, -77.2% over six months, -76.3% year to date, -24.6% in the last week.

12 Months vs Market
TCRX
-87.8%
DIA
+10.9%
SPY
+15.7%
QQQ
+22.9%
IWM
+13.2%

Over the past 12 months TCRX returned -87.8% versus DIA (Dow) +10.9%, SPY (S&P 500) +15.7%, QQQ (Nasdaq 100) +22.9% and IWM (Russell 2000) +13.2%.

Volume & Liquidity 0.66× 3-mo avg
Today 522,962 3-mo avg 790.4K
1W
715.9K
1M
801.8K
3M
790.4K
6M
841.3K
YTD
745.1K
1Y
764.9K

TCRX most recently traded 522,962 shares against a 3-month average daily volume of 790.4K.

More News

Read More
Here are the top movers in Wednesday's session. ↗
September 02, 2026
Via Chartmill
Which stocks are gapping on Wednesday? ↗
September 02, 2026
Via Chartmill
News headline image
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
September 02, 2026
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
July 29, 2026
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 24, 2026
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
June 22, 2026
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
June 03, 2026
From Cellares
Via Business Wire
News headline image
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 06, 2026
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
April 27, 2026
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 04, 2026
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
February 26, 2026
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
February 25, 2026
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
December 06, 2025
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
December 03, 2025
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 12, 2025
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
November 05, 2025
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Kimberly-Clark Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
November 04, 2025
Via Benzinga
News headline image
Which stocks are moving on Monday? ↗
November 03, 2025
Via Chartmill
News headline image
Top movers analysis in the middle of the day on 2025-11-03: top gainers and losers in today's session. ↗
November 03, 2025
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
November 03, 2025
Via Benzinga
News headline image
Gapping stocks in Monday's session ↗
November 03, 2025
Via Chartmill
News headline image
Discover the top movers in Monday's pre-market session. ↗
November 03, 2025
Via Chartmill

Frequently Asked Questions

Is TScan Therapeutics, Inc. - Common Stock publicly traded?
Yes, TScan Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does TScan Therapeutics, Inc. - Common Stock trade on?
TScan Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for TScan Therapeutics, Inc. - Common Stock?
The ticker symbol for TScan Therapeutics, Inc. - Common Stock is TCRX on the Nasdaq Stock Market
What is the current price of TScan Therapeutics, Inc. - Common Stock?
The current price of TScan Therapeutics, Inc. - Common Stock is 0.2416
When was TScan Therapeutics, Inc. - Common Stock last traded?
The last trade of TScan Therapeutics, Inc. - Common Stock was at 10/09/26 03:15 PM ET
What is the market capitalization of TScan Therapeutics, Inc. - Common Stock?
The market capitalization of TScan Therapeutics, Inc. - Common Stock is 5.79M
How many shares of TScan Therapeutics, Inc. - Common Stock are outstanding?
TScan Therapeutics, Inc. - Common Stock has 6M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap